Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04918381
Other study ID # NP-TR-014
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2, 2021
Est. completion date July 22, 2022

Study information

Verified date December 2022
Source Pulse Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.


Description:

The study will enroll healthy adult subjects with confirmed low-risk (superficial and nodular) BCC lesion(s) by biopsy, excluding BCCs located on the face, neck, scalp, axilla, hands, feet, and genitals not exceeding 1.5 cm. Macrophotography of all study BCCs will be captured and clinically assessed by the site investigator for characterization of healing and scar appearance prior to and post-surgical excision. All subjects will be followed at 3, 7, 14, 30 and 60-days post-CellFX procedure and at 14, 30 and 60-days post-excision. Adverse events will be documented.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 22, 2022
Est. primary completion date March 2, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 85 Years
Eligibility Inclusion Criteria: - Subject is at least 22 and no older than 85 years of age. - Subject has 1-2 primary, non-recurrent, superficial, or nodular visible basal cell carcinoma lesion up to 1.5 cm in size with well-defined borders that has been verified by biopsy. - Lesion(s) is appropriate for full linear excision with 5 mm margins. - Subject is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. - Subject gives voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. - Subject is willing to have BCC lesion(s) treated in a single treatment session and must comply with all study procedures including follow-up visits. - Subject consents to have photographs taken of the BCC lesion(s). - Subject agrees to refrain from using all other lesion removal products or treatments (topical medication including over-the-counter medications or treatments from PI or another physician) during the study period. - Subject agrees to refrain from prolonged sun exposure of the treatment area during the study period. Exclusion Criteria: - Subject has an implantable electronic medical device (i.e., pacemaker, implantable cardioverter defibrillator). - Subject has an active infection or history of infection in designated test area within four weeks prior to treatment. - Subject is not willing or able to sign the Informed Consent. - Subject is known to be immune compromised/has a history of immunosuppression (e.g., organ transplant, long-term use of psoralen) or genetic disease (e.g., nevoid basal cell carcinoma syndrome [Gorlin syndrome], xeroderma pigmentosum). - The basal cell carcinoma lesion intended for treatment with the CellFX System is on the face, neck, scalp, axilla, hands, feet, or genitals. - The basal cell carcinoma intended for treatment with the CellFX System is a high-risk BCC subtype including perineurial, infiltrative, sclerosing, morpheaform, desmoplastic, micronodular, basosquamous or exhibiting aggressive growth patterns. - Subject is known to be a keloid producer. - Subject has allergies to Lidocaine or Lidocaine-like products. - Subject has a history of radiation to the area intended for treatment. - Subject has current or prior metastatic BCC. - Subject is currently being treated or has been previously treated with Sonidegib or Vismodegib. - Subject has recurrent BCC lesions. - Subject has a systemic infection. - Subject has a history of epilepsy. - Subject has a history of cardiac arrhythmia, myocardial infarction or structural heart disease. - Subject is employed by the sponsor, clinic site, or entity associated with the conduct of the study. - Subject has any condition or situation which, in the Investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study. - Subject has a history of use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study, with the exception of participation in a COVID vaccination related clinical trial.

Study Design


Intervention

Device:
CellFX System
Nano-Pulse Stimulation (NPS)

Locations

Country Name City State
United States Moy-Fincher-Chipps Dermatology Beverly Hills California
United States Clinical Research Center of the Carolinas Charleston South Carolina
United States SkinCare Physicians Chestnut Hill Massachusetts
United States Palm Harbor Dermatology Clearwater Florida
United States Surgical Dermatology Group Vestavia Hills Alabama

Sponsors (1)

Lead Sponsor Collaborator
Pulse Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Lesions With BCC Histological Clearance The primary effectiveness endpoint is the total number of lesions with complete histological clearance of the BCC lesion during histological review of microscopic analysis using H & E slides. Counts and proportions will be assessed. 60-days post-CellFX procedure
Primary Number of Participants With Treatment Related Serious Adverse Events No serious adverse events related to CellFX Treatment or Procedure 60-days post-CellFX procedure
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04552990 - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma Phase 2
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Recruiting NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients Phase 2
Recruiting NCT04570683 - Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas Early Phase 1
Recruiting NCT06279143 - The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes